SJS Investment Consulting’s BioCryst Pharmaceuticals BCRX Stock Holding History

SJS Investment Consulting’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8K	Buy	1,083 +1,069	+7,636%	+$9.67K	﹤0.01%	1050
2026 Q1	$134	Hold	14	–	–	﹤0.01%	2074
2025 Q4	$110	Buy	+14	New	+$101	﹤0.01%	1936
2024 Q2	–	Sell	-20	Closed	-$102	–	1668
2024 Q1	$102	Buy	20 +2	+11%	+$11	﹤0.01%	1565
2023 Q4	$108	Sell	18 -7	-28%	-$41	﹤0.01%	1543
2023 Q3	$177	Buy	25 +11	+79%	+$79	﹤0.01%	1473
2023 Q2	$99	Hold	14	–	–	﹤0.01%	1514
2023 Q1	$117	Sell	14 -12	-46%	-$116	﹤0.01%	1443
2022 Q4	$298	Buy	26 +14	+117%	+$175	﹤0.01%	1345
2022 Q3	$0	Buy	+12	New	+$154	﹤0.01%	1059
2022 Q1	$0	Buy	+2	New	+$32	﹤0.01%	739

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SJS Investment Consulting's BCRX Position: Q2 2026 in Review

SJS Investment Consulting increased its BioCryst Pharmaceuticals (BCRX) stake by 7,636% in Q2 2026, buying an estimated $9.67K and bringing the position to 1,083 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

SJS Investment Consulting first reported a position in BCRX in Q1 2022 and has held it in 11 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

SJS Investment Consulting held 1,083 shares of BioCryst Pharmaceuticals worth $10.8K as of Q2 2026.
SJS Investment Consulting bought 1,069 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $9.67K.
BioCryst Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1050 holding.
SJS Investment Consulting first reported a position in BioCryst Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.